ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 327 filers reported holding ROYALTY PHARMA PLC in Q1 2023. The put-call ratio across all filers is 0.47 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,555,562 | -21.9% | 610,006 | -11.6% | 0.00% | -33.3% |
| Q2 2023 | $21,209,001 | -17.5% | 689,948 | -3.3% | 0.01% | -14.3% |
| Q1 2023 | $25,695,407 | -77.4% | 713,167 | -75.3% | 0.01% | -78.8% |
| Q4 2022 | $113,935,764 | -9.4% | 2,882,990 | -7.9% | 0.03% | -17.5% |
| Q3 2022 | $125,796,000 | +12.9% | 3,130,851 | +18.1% | 0.04% | +17.6% |
| Q2 2022 | $111,469,000 | +318.7% | 2,651,493 | +288.0% | 0.03% | +385.7% |
| Q1 2022 | $26,623,000 | +22.9% | 683,367 | +25.7% | 0.01% | +40.0% |
| Q4 2021 | $21,663,000 | -4.6% | 543,599 | -13.5% | 0.01% | -16.7% |
| Q3 2021 | $22,704,000 | -20.1% | 628,210 | -9.4% | 0.01% | -14.3% |
| Q2 2021 | $28,427,000 | -1.7% | 693,518 | +4.7% | 0.01% | -12.5% |
| Q1 2021 | $28,904,000 | +174.0% | 662,633 | +214.4% | 0.01% | +166.7% |
| Q4 2020 | $10,548,000 | -69.9% | 210,735 | -74.7% | 0.00% | -75.0% |
| Q3 2020 | $35,008,000 | -3.9% | 832,121 | +10.9% | 0.01% | -7.7% |
| Q2 2020 | $36,413,000 | – | 750,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $294,957,000 | 88.74% |
| Vantage Consulting Group Inc | 8,705,551 | $379,735,000 | 76.23% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $116,930,000 | 72.07% |
| HARVARD MANAGEMENT CO INC | 10,714,284 | $467,357,000 | 26.11% |
| ROBERT WOOD JOHNSON FOUNDATION | 970,151 | $4,231,798,000 | 21.59% |
| Brown University | 381,759 | $16,652,000 | 11.44% |
| Overbrook Management Corp | 771,155 | $33,638,000 | 7.48% |
| SpiderRock Advisors, LLC | 778,800 | $34,236,000 | 4.79% |
| Renaissance Capital LLC | 452,948 | $19,758,000 | 2.93% |
| Lagoda Investment Management, L.P. | 104,835 | $4,573,000 | 2.28% |